Bitget has expanded its stock-contract offerings by adding perpetual contracts for Danaher (DHR) and American Telephone and Telegraph (AT&T). These new contracts settle in USDT and allow traders to use leverage of up to 20 times. This addition increases Bitget's total stock contracts to 376 and supports continuous trading around the clock, seven days a week. The move follows a recent expansion of five contracts on October 22, enhancing Bitget's position in the derivatives market.
Bitget's addition of Danaher and TSTOCK perpetual contracts comes as of Oct 24, 2026 02:31 WIB. For readers following major cryptocurrencies on Pluang, here is the market snapshot: out of 50 priced assets, 36 rose and 13 fell today. Notable movers include COTI at Rp202 with a 1-day change of +3.90% and Pluang order activity showing 84% Sell / 16% Buy, and VeChain at Rp130 with a 1-day change of +3.33% and 88% Sell / 12% Buy activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
